Skip to main content

Table 2 Health-care resources used after diagnosis of CNS diagnosis

From: Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study

Chemotherapy including targeted therapy 185/218 (84.8%)
Use of trastuzumab- or lapatinib- based therapies Trastuzumab Lapatinib Both All
  1st line (n = 175) 118 (67.4%) 26 (14.9%) 2 (1.1%) 146 (83.4%)
  2nd line (n = 127) 63 (49.6%) 34 (26.8%) 1 (0.8%) 98 (77.2%)
  3rd line (n = 81) 39 (48.1%) 15 (18.5%) 2 (2.5%) 56 (69.1%)
  4th line (n = 48) 23 (47.9%) 9 (18.8%) 2 (4.2%) 34 (70.9%)
  5th line and more (n = 27) 7 (25.9%) 6 (22.2%) None 13 (48.1%)
Radiotherapy 200/218 (91.7%)
  Whole brain radiotherapy only 166/218 (77.3%)
  1 cycle radiotherapy 173/218 (86.8%)
  2 cycles radiotherapy (SRS boost or EBRT) 25/218 (12.5%)
  Second SRS 2/218 (1.0%)
  SRS only 21/218 (9.6%)
  Both (whole-brain radiotherapy and SRS) 13/218 (6.0%)
  Whole-brain radiotherapy 2D 96/193 (49.7%)
  Whole-brain radiotherapy 3D 97/193 (50.3%)
  Median fractions per patient 10 (1–28)
Neurosurgery 29/218 (13.3%)
Emergency unit visits 159/218 (73%)
  Mean length of stay 14.9 days (95% - CI 13.2-16.7)
  Median length of hospital stay (days, range) 9 days (range 1–221)
  Mean number of complications leading to hospitalisation 0.44 (95/218)
  1. Data are presented as number of patients (%). EBRT: external beam radiotherapy; SRS: stereotactic radiosurgery; 2D: two-dimensional; 3D: three dimensional.